Navigation Links
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
Date:11/7/2012

en Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA for Contrave or an NDA for Empatic; the therapeutic and commercial value of Contrave or Empatic; Orexigen's ability to maintain sufficient capital; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission August 9, 2012 and which is available from the SEC's website (www.sec.gov) and on Orexigen's website (www.orexigen.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

 Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491 Orexigen Therapeutics, Inc.Balance Sheets(In thousands, except share and par value amounts)September 30,December 31,20122011(Unaudited)AssetsCurrent assets:Cash and cash equivalents 

$   56,057$  101,749Investment securities, available-for-sale 

52,22745,844Prepaid expenses and other current assets 

1,5071,126Total current assets 

109,791148,719Property and equipment, net 

166439Restricted cash 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
(Date:12/17/2014)... 2014 , The ... hub of information concerning the biopharmaceutical Group,s national and international ... addition to the recently launched institutional website that is receiving ... enriched by a new chapter in the fascinating story of ... detailed and panoramic hub on the world of clinical research, ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 CVS Caremark Corporation (NYSE: CVS ... Executive Officer, will be making a presentation to investors ... June 1, 2011. Mr. Merlo is scheduled to present ... An audio webcast of the presentation will be ...
... U.S. Food and Drug Administration today approved Edurant (rilpivirine) ... of HIV-1 infection in adults who have never taken ... ) Edurant belongs to a class ... The drug works by blocking HIV viral replication. Edurant ...
Cached Medicine Technology:FDA Approves New HIV Treatment 2FDA Approves New HIV Treatment 3
(Date:12/21/2014)... 2014 The Oncology Institute of Hope and ... Ana and Whittier offices. The Hope for the Holidays Toy ... patients and their families during the holiday season. This year, ... 70 children between both offices. This event continues to be ... community service team, store managers and assistant managers came out ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly bamboo flooring ... bamboo flooring promotion for the coming 2015. , ... and offers the best bamboo products and services ... all customers can enjoy a special discount, up ... BambooIndustry.com from press releases. , The bamboo flooring ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 ... the healthcare sector have benefited the Massage Services ... the discretionary characteristics of industry products, the anticipated 1.0% ... five-year period has provided consumers with the means to ... that have received a massage in a given year ...
(Date:12/20/2014)... 20, 2014 The print component of ... a distribution of approximately 160,000 copies and an estimated ... through a vast social media strategy and across a ... explore the digital version of the campaign, click ... interview with the ladies of CTV’s The Social. ...
(Date:12/20/2014)... December 20, 2014 The Doctor’s Office Urgent ... the better part of a decade. They’ve treated over ... better, faster healthcare alternative to the Paramus area. ... three new additions to their staff of top-notch board certified ... Zeiger MD. These new doctors will work tirelessly ...
Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2
... , New York, N.Y. -- The changes in brain ... detectable in children as young as 6 months, according ... Journal of Psychiatry . While core behaviors associated with ... be identified after a baby,s first birthday, researchers found ...
... the initial steps that occur in the body when type ... adult. The analysis comes from a team of researchers ... have expertise both in the laboratory and in treating patients. ... 48 hours of their diagnosis with type 1 diabetes, an ...
... THURSDAY, Feb. 16 (HealthDay News) -- When it comes ... weight training may be more effective than stretching or ... "reconfirm our notions that exercise plays an important part ... outside expert, Dr. Nora Chan, director of the Movement ...
... cancer, which killed 15,000 American women last year, is ... of Wayne State University School of Medicine researchers recently ... cancer patients. The "freeze and destroy" technique is ... Peter Littrup, M.D., professor of radiology in the School ...
... HealthDay Reporter , THURSDAY, Feb. 16 (HealthDay ... struggle with heart failure, experts say new treatments have ... for these patients. "The present environment for heart ... that will truly remove the term ,failure, from the ...
... carbon nanoparticles shows potential to enhance treatment for head-and-neck ... new research by Rice University and the University of ... a path for further research into therapy customized to ... nanoparticles to encapsulate chemotherapeutic drugs and sequester them until ...
Cached Medicine News:Health News:Researchers see differences in Autism brain development as early as 6 months 2Health News:As diabetes emerges, researchers track disease's first steps 2Health News:As diabetes emerges, researchers track disease's first steps 3Health News:As diabetes emerges, researchers track disease's first steps 4Health News:Weight Training May Help Parkinson's Patients Retain Function 2Health News:Wayne State proves targeted tumor freezing therapy increases ovarian cancer survival 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 3Health News:Nanoparticles may enhance cancer therapy 2Health News:Nanoparticles may enhance cancer therapy 3Health News:Nanoparticles may enhance cancer therapy 4
Large....
These products are supplied non-sterile and must be sterilized before use. For insertion through the smokevac and nezhat-dorsey trumpet valve in conjunction with the universal instrument insert adapt...
... Utilizing breakthrough electro-optical and rotary ... SUPRA is capable of obtaining ... pupils as narrow as 2.0mm. ... precise diagnostic results when dealing ...
Sterile perfluorocarbon for intraocular Application....
Medicine Products: